BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 18360909)

  • 1. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
    Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
    Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
    Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
    Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
    Roth SD; Sapp M; Streeck RE; Selinka HC
    Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an HPV vaccine for a broad spectrum of high-risk types.
    Kanda T; Kondo K
    Hum Vaccin; 2009; 5(1):43-5. PubMed ID: 18690012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.
    Christensen ND; Kirnbauer R; Schiller JT; Ghim SJ; Schlegel R; Jenson AB; Kreider JW
    Virology; 1994 Nov; 205(1):329-35. PubMed ID: 7526536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
    Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
    Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.
    Nakao S; Mori S; Kondo K; Matsumoto K; Yoshikawa H; Kanda T
    Virology; 2012 Dec; 434(1):110-7. PubMed ID: 23051711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
    Xu YF; Zhang YQ; Xu XM; Song GX
    Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.